Table 1 Baseline characteristics of patients
IFNB (n=9) | NTZ (n=10) | p-value | |
|---|---|---|---|
Females, n (%)* | 3 (33%) | 6 (60%) | 0.370 |
Age, [years] ‡ | 39 (24–48) | 43 (20–60) | 0.460 |
Disease duration, [years] ‡ | 12 (2–23) | 10 (5–17) | 0.712 |
Number of NTZ infusions (run-in period) at baseline‡ | 21 (12–49) | 25.5 (13–45) | 0.661 |
Annualized relapse rate ‡ | |||
- during 2 years prior to run-in period NTZ | 1 (0.5-2.5) | 1.3 (0.5-2.5) | 0.661 |
- during run-in period NTZ | 0 (0) | 0(0–1.3) | 0.497 |
EDSS ‡ | |||
- during 2 years prior to run-in period NTZ | 2 (1–3.5) | 2.5 (1–3.5) | 0.616 |
- at randomization | 3 (1.5-3.5) | 3 (1.5-3.5) | 0.714 |
Therapy before run-in therapy with NTZ n (%) * | |||
- no treatment | 1 (11%) | 2 (20%) | 1.000 |
- Glatiramer acetate | 1 (11%) | 2 (20%) | 1.000 |
- IFNbeta 1a im | 1 (11%) | 2 (20%) | 1.000 |
- IFNbeta 1a sc | 2 (22%) | 3 (30%) | 1.000 |
- IFNbeta 1b | 4 (44%) | 1 (10%) | 0.141 |